Literature DB >> 12200826

Fibrillary glomerulonephritis: early diagnosis associated with steroid responsiveness.

Michael Dickenmann1, Stefan Schaub, Volker Nickeleit, Michael Mihatsch, Jürg Steiger, Felix Brunner.   

Abstract

Patients with fibrillary glomerulonephritis usually present with nephrotic proteinuria, microscopic hematuria, impaired renal function, and hypertension; 50% develop end-stage renal disease within a few years. There is no known effective therapy for fibrillary glomerulonephritis. We describe three patients with biopsy-proven fibrillary glomerulonephritis, in whom pathognomonic fibrillar deposits of 20-nm diameter were seen by electron microscopy. All patients had nephrotic syndrome and normal renal function at the time of diagnosis. They were treated initially with prednisone, 1 mg/kg body weight, then tapered individually according to the clinical course. Additional therapy consisted of an angiotensin-converting enzyme inhibitor and diuretics. Proteinuria disappeared in two of three patients after 9 and 12 months of therapy. In one patient, proteinuria was reduced from 7.49 mg/mg creatinine to 0.63 mg/mg creatinine after 6 months of treatment. The kidney function remained normal in all three cases. Two patients are now free of steroid therapy for 9 and 6 months. They show no signs of recurrence of kidney disease and have normal renal function without significant proteinuria. Steroid therapy in patients with biopsy-proven fibrillary glomerulonephritis, starting with prednisone, 1 mg/kg body weight, and tapered individually according to the clinical course, is a promising strategy. Early start of treatment in patients with preserved renal function seems to be crucial for a favorable outcome. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200826     DOI: 10.1053/ajkd.2002.34933

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Fibrillary glomerulonephritis associated with monoclonal gammopathy of undetermined significance showing lambda-type Bence Jones protein.

Authors:  Tomoaki Nagao; Takafumi Okura; Ken-Ichi Miyoshi; Sanae Watanabe; Seiko Manabe; Mie Kurata; Jun Irita; Tomikazu Fukuoka; Jitsuo Higaki
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

2.  Treatment of fibrillary glomerulonephritis by corticosteroids and tripterygium glycoside tablets: A case report.

Authors:  Zhao-Yu Lu; Hai-Feng Yang; Yu Peng; Yin Li; Zi-Chang Yin; Fu-Hua Lu; Xu-Sheng Liu
Journal:  Chin J Integr Med       Date:  2016-03-29       Impact factor: 1.978

3.  Complete remission of DnaJ homolog subfamily B member 9-positive fibrillary glomerulonephritis following steroid monotherapy in an elderly Japanese woman.

Authors:  Takahiro Uchida; Shuuhei Komatsu; Takashi Sakai; Aki Kojima; Sachiko Iwama; Kentaro Sugisaki; Takashi Oda
Journal:  CEN Case Rep       Date:  2021-03-03

Review 4.  Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).

Authors:  Nattawat Klomjit; Mariam Priya Alexander; Ladan Zand
Journal:  Kidney360       Date:  2020-07-08

5.  Fibrillary glomerulonephritis presenting as rapidly progressive renal failure in a young female: a case report.

Authors:  Sandeep Mahajan; Vikram Kalra; A K Dinda; S C Tiwari; S K Agarwal; D Bhowmik; S C Dash
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.266

6.  Plasmapheresis leading to remission of refractory nephrotic syndrome due to fibrillary glomerulonephritis: a case report.

Authors:  Rainer U Pliquett; Peter Mohr; Badr El Din Mukhtar; Matthias Girndt; Silke Markau
Journal:  J Med Case Rep       Date:  2012-04-24

7.  A case of membranoproliferative glomerulonephritis associated with curved fibril deposition.

Authors:  Ikuyo Narita; Michiko Shimada; Takeshi Fujita; Reiichi Murakami; Masayuki Nakamura; Norio Nakamura; Hideaki Yamabe; Ken Okumura
Journal:  BMC Nephrol       Date:  2015-09-15       Impact factor: 2.388

8.  Fibrillary glomerulonephritis with small fibrils in a patient with the antiphospholipid antibody syndrome successfully treated with immunosuppressive therapy.

Authors:  Muhammad M Javaid; Helen Denley; Senyo Tagboto
Journal:  BMC Nephrol       Date:  2007-05-09       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.